M. Reck

New England Journal of Medicine · 2008–2023

A researcher in the Science corpus: 28 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom M. Reck trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Schiller
2. J. Wolchok
3. N. Ferrara
4. D. Pardoll

Who trusts M. Reck overall

1. N. Vasudev
2. M. Hellmann
3. B. Chan
4. C. Viallard

Papers from M. Reck's perspective

Ordered by how strongly the researchers M. Reck trusts endorse each paper. Same corpus, a different order for every researcher.

1. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer… (Journal of the National Cancer Institute)
2. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3… (The Lancet)
5. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. (Journal of Clinical Oncology)
6. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (Annals of Oncology)
7. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study (Journal of Clinical Oncology)
8. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study (The Lancet Oncology)
9. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (Journal of Clinical Oncology)
10. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. (Journal of Clinical Oncology)

Their papers

• Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. (2023) — 727 citations
• Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer (2022) — 990 citations
• Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021) — 870 citations
• Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) (2021) — 695 citations
• First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. (2021) — 1,049 citations
• Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2020) — 855 citations
• Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. (2019) — 822 citations
• Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. (2019) — 2,232 citations
• Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. (2019) — 1,408 citations
• Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (2018) — 2,690 citations
• Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer (2018) — 5,500 citations
• Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC (2018) — 3,127 citations
• First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer (2018) — 2,798 citations
• Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC (2018) — 2,353 citations
• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). (2017) — 794 citations
• Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. (2017) — 653 citations
• First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer (2017) — 1,383 citations
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. (2016) — 8,730 citations
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (2015) — 7,839 citations
• Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. (2014) — 889 citations